Skip to main content
. 2012 May 17;106(12):1997–2003. doi: 10.1038/bjc.2012.145

Figure 2.

Figure 2

Association between JNK activation, decreased time to progression and OS in patients treated with sorafenib. The Kaplan–Meier method was used to determine progression-free survival (A) and cumulative survival (B). The log-rank test was used to compare progression-free survival and cumulative survival between patients grouped according to phospho-c-Jun expression levels.